The first‐in‐human study of teliso‐v, conducted outside of Japan (NCT02099058), demonstrated its favorable safety and tolerability profiles, with encouraging evidence of antitumor activity in patients with c‐Met–positive NSCLC.3 This evidence concerns the gene MET and non-small cell lung carcinoma.